MarketCap
Facebook
X
Telegram
Solid Biosciences Market Cap | SLDB
As of October 25, 2026 Solid Biosciences has a market cap of $ 518 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Solid Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 623 M | 226 M | 243 M | 38.6 M | 12.5 M | 26.2 M | 136 M | 846 M | 725 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 846 M | 12.5 M | 320 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M |  USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M |  Canada |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | USA |
 |
Perrigo Company plc
PRGO
|
1.96 B | $ 15.96 | -2.5 % | $ 2.21 B | USA |
 |
Aurora Cannabis
ACB
|
224 M | $ 3.88 | -2.27 % | $ 213 M | Canada |
 |
Evolus
EOLS
|
271 M | $ 7.01 | -5.4 % | $ 452 M | USA |
 |
Tricida
TCDA
|
408 M | - | - | $ 3.25 M | USA |
 |
Harrow Health
HROW
|
1.93 B | $ 28.44 | 1.03 % | $ 1.05 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
Organogenesis Holdings
ORGO
|
337 M | $ 0.99 | -3.57 % | $ 125 M | USA |
 |
Pacira BioSciences
PCRX
|
1.17 B | $ 36.42 | 0.22 % | $ 1.62 B | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Radius Health
RDUS
|
393 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
1.85 M | $ 1.11 | -3.48 % | $ 1.87 M | USA |
 |
Sundial Growers
SNDL
|
348 M | $ 1.29 | 0.17 % | $ 333 M | Canada |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
187 K | - | - | $ 36.6 M | USA |
 |
Tilray
TLRY
|
614 M | $ 2.81 | -4.1 % | $ 314 M | Canada |
 |
TherapeuticsMD
TXMD
|
23 M | $ 1.8 | -2.7 % | $ 20.8 M | USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Veru
VERU
|
84.9 M | $ 2.24 | -2.18 % | $ 32.8 M | USA |
 |
PLx Pharma
PLXP
|
119 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 18.0 | -2.6 % | $ 20.7 B | USA |
 |
Lannett Company
LCI
|
23 M | - | 1.15 % | $ 7.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |
 |
cbdMD
YCBD
|
3.58 M | $ 0.36 | -5.79 % | $ 1.45 M | USA |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
OptiNose
OPTN
|
12.8 M | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
396 B | - | 1.64 % | $ 400 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
84.8 M | $ 8.49 | 0.12 % | $ 126 M | USA |
 |
Canopy Growth Corporation
CGC
|
292 M | $ 0.68 | 1.58 % | $ 203 M | Canada |
 |
Emergent BioSolutions
EBS
|
452 M | $ 6.23 | 0.16 % | $ 333 M | USA |
 |
Rockwell Medical
RMTI
|
33.8 M | $ 6.94 | -1.7 % | $ 250 M | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 3.79 | -0.66 % | $ 189 M | USA |
 |
OrganiGram Holdings
OGI
|
151 M | $ 0.93 | -1.11 % | $ 88.6 M | Canada |
 |
Bausch Health Companies
BHC
|
2.03 B | $ 6.44 | -0.77 % | $ 2.39 B | Canada |
 |
Cronos Group
CRON
|
736 M | $ 3.35 | -2.76 % | $ 1.28 B | Canada |
 |
China Pharma Holdings
CPHI
|
2.75 M | $ 0.66 | -2.69 % | $ 2.83 M |  China |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 3.27 | -0.61 % | $ 129 M | USA |
 |
HEXO Corp.
HEXO
|
276 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | USA |